Cell Therapeutics’ (CTIC) fans are a staple of our fanbase and continuously put anything CTIC/Pixantrone/Opaxio/Adam Feuerstein in our Top Ten each week. Thanks guys!!

But what else is poppin’ on IguanaBio this month? Let’s take a look at What’s Hot in June…

• The drama over Hemispherx Biopharma heats up, and still no word on Ampligen…

• What’s the status on the Pfizer/Wyeth merger?

• Is the Solvay deal fizzling?

• Genasense looks tired…

• We have a discussion board, people!!!

• Can Arena pull off a deal before the BLOSSOM data in September?

• 16,000 Merck and Schering-Plough reps NOT HAPPY — polishing bag-packing skills.

• FDA Chief’s husband is a top guy at hedge fund Renaissance Technologies. What to do?

• Where are the EU biotech deals?

• Uh-oh, is Amgen’s denosumab ready for prime-time?

• Oscient axes its ENTIRE SALES FORCE!!!

• What about Genta’s oral taxane – does it stand a chance? Find out.

• That guy from Brokeback Mountain is getting ready to sell Viagra.

• Are you a B-rated CEO? No worries – this guy says “You Can Do It!!”

• Does the world need another inhaled insulin? Check out what people are saying.

• Finally, Pfizer admits that generics have value.

And that’s What’s Hot in June in the non-CTIC world…

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts